Can Anti-Diarrhea meds make a powerful breast cancer drug safer?

NCT ID NCT05520723

Completed Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding loperamide (Imodium) and a white blood cell booster (G-CSF) could reduce severe diarrhea and low white blood cell counts caused by the drug Trodelvy in people with advanced breast cancer. Fifty patients with metastatic triple-negative or luminal breast cancer who had already tried other treatments took part. The goal was to see if these supportive medicines could make Trodelvy easier to tolerate without reducing its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab govitecan (Trodelvy) plus loperamide and G-CSF
What this could lead to: If successful, this approach could make Trodelvy safer and more tolerable for patients with advanced breast cancer, reducing severe side effects like diarrhea and infections.
What could go wrong: This is a small, early-phase trial with only 50 participants and no comparison group. The supportive medications may not significantly reduce side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm breast tumor luminal A or B hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HR+/HER2- BREAST CANCER BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Hospital Arnau de Vilanova

Lleida, Lleida, Spain
Hospital Quiron San Camilo- Ruber Juan Bravo

Madrid, Madrid, 28006, Spain
Hospital Quirón Valencia

Valencia, Valencia, Spain
Hospital Ramón y Cajal

Madrid, Spain
Hospital Universitario A Coruña

A Coruña, A Coruna, Spain
Hospital Universitario Clínico San Cecilio de Granada

Granada, Spain
Hospital Universitario Donostia

San Sebastián, Donostia, 20014, Spain
Hospital Universitario General de Catalunya

Sant Cugat del Vallès, Barcelona, 08190, Spain
Hospital Universitario Virgen del Rocio

Seville, Spain
Hospital de Sant Joan Despí - Moises Broggi

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.